Effect of Pyridoxine and Ascorbic acid on Mild Cognitive Impairment in Post-Menopausal Wome
- Conditions
- Health Condition 1: G319- Degenerative disease of nervous system, unspecified
- Registration Number
- CTRI/2023/03/051131
- Lead Sponsor
- SRM COLLEGE OF PHARMACY
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. MoCA Score 18-25
2. Menopausal women (taken as complete cessation of menstruation for at least 1 year/12 cycles)
1. History of recent or current Estrogen or hormonal replacement therapy
2. Known hypertensive, diabetic, renal disease, endocrine disorders, overt nutritional deficiency states, liver disease or those having history of psychiatric illness.
3. History of Women having estrogen secreting ovarian tumors, for e.g., granulosa and theca cell tumors, tumors of the adrenal gland.
4. Known history of neurological disorders including CVA, space occupying lesions, epilepsy and developmental anomalies.
5. Women, who are physically unable to hear, read or understand written or explained instructions properly, or may have a motor deficit that affects writing and drawing skills.
6. Women, who are already in any of the antioxidant or dietary supplement therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method